Cargando…

Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo‐controlled multicentre trial

BACKGROUND AND AIMS: Incomplete microscopic colitis (MCi) is a subtype of microscopic colitis (MC). Budesonide is recommended as a first‐line treatment for MC. However, randomised trials on efficacy of treatment in MCi are missing. We therefore performed a randomised, placebo‐controlled trial to eva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Münch, Andreas, Mihaly, Emese, Nagy, Ferenc, Madisch, Ahmed, Kupčinskas, Juozas, Miehlke, Stephan, Bohr, Johan, Bouma, Gerd, Guardiola, Jordi, Belloc, Blanca, Shi, Chunliang, Aust, Daniela, Mohrbacher, Ralf, Greinwald, Roland, Munck, Lars Kristian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435258/ https://www.ncbi.nlm.nih.gov/pubmed/34414678 http://dx.doi.org/10.1002/ueg2.12131

Ejemplares similares

Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial
por: Münch, Andreas, et al.
Publicado: (2016)

Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6‐week open‐label trial of the EOS‐2 Programme
por: Miehlke, Stephan, et al.
Publicado: (2022)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
por: Sandborn, W. J., et al.
Publicado: (2015)

Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis
por: Kruis, Wolfgang, et al.
Publicado: (2023)

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
por: Kruis, W, et al.
Publicado: (2009)

First Multicenter Study of Modified Release Phosphatidylcholine “LT-02” in Ulcerative Colitis: A Randomized, Placebo-Controlled Trial in Mesalazine-Refractory Courses
por: Karner, Max, et al.
Publicado: (2014)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse
por: Arrieta, M C, et al.
Publicado: (2008)

Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition
por: Binion, D G, et al.
Publicado: (2008)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
por: Tursi, Antonio, et al.
Publicado: (2010)

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association
por: Kaplan, Gilaad G, et al.
Publicado: (2010)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis
por: Aherne, Carol M, et al.
Publicado: (2011)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
por: Cayatte, Corinne, et al.
Publicado: (2012)

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Abnormally expressed ER stress response chaperone Gp96 in CD favours adherent-invasive Escherichia coli invasion
por: Rolhion, Nathalie, et al.
Publicado: (2010)

Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers
por: Roberts, Carol L, et al.
Publicado: (2010)

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Increased Epithelial Gaps in the Small Intestine Are Predictive of Hospitalization and Surgery in Patients With Inflammatory Bowel Disease
por: Turcotte, Jean-Francois, et al.
Publicado: (2012)

A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Factors affecting outcomes in Crohn's disease over 15 years
por: Cosnes, Jacques, et al.
Publicado: (2012)

Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease
por: Kiesslich, R, et al.
Publicado: (2011)

Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability
por: Cani, P D, et al.
Publicado: (2009)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
por: Hébuterne, Xavier, et al.
Publicado: (2013)

Therapeutic Effect of Vitamin D Supplementation in a Pilot Study of Crohn's Patients
por: Yang, Linlin, et al.
Publicado: (2013)

Propionyl-L-Carnitine is Efficacious in Ulcerative Colitis Through its Action on the Immune Function and Microvasculature
por: Scioli, Maria Giovanna, et al.
Publicado: (2014)

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
por: Mayer, Lloyd, et al.
Publicado: (2014)

Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-Control questionnaire
por: Bodger, Keith, et al.
Publicado: (2014)

Bacterial protein signals are associated with Crohn’s disease
por: Juste, Catherine, et al.
Publicado: (2014)

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
por: Cornillie, Freddy, et al.
Publicado: (2014)

Study of the Viral and Microbial Communities Associated With Crohn's Disease: A Metagenomic Approach
por: Pérez-Brocal, Vicente, et al.
Publicado: (2013)

Mouse Paneth cell antimicrobial function is independent of Nod2
por: Shanahan, Michael T, et al.
Publicado: (2014)

Higher Activity of the Inducible Nitric Oxide Synthase Contributes to Very Early Onset Inflammatory Bowel Disease
por: Dhillon, Sandeep S, et al.
Publicado: (2014)

Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2013)

Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease
por: Koelink, Pim J, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fjgcf1hk33oo49i012fnfde58s